Review paper<br>Subcutaneous methotrexate injection in the treatment of rheumatoid arthritis

Jerzy Świerkot

eISSN: 2084-9834
ISSN: 0034-6233

Reumatologia/Rheumatology

Current issue Archive Manuscripts accepted About the journal Supplements Editorial board Reviewers Abstracting and indexing Subscription Contact Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

6/2007
vol. 45

Send email

Copy url:

abstract:

Review paper
Subcutaneous methotrexate injection in the treatment of rheumatoid arthritis

Jerzy Świerkot

Reumatologia 2007; 45, 6: 407–414

Online publish date: 2007/12/20

View full text Get citation

Methotrexate (MTX) is the most frequently used drug in the treatment of rheumatoid arthritis. Oral administration has long been the standard way of administration. Generally it is well tolerated adverse some side effects (gastrointestinal) may lead to discontinuation of therapy. A significant lower bioavailability could be observed when MTX was administered orally while the bioavailability after subcutaneous application was similar to the intramuscular treatment. In some patients who did not tolerate or showed no significant clinical improvement under oral MTX, suppression of disease activity could be seen after switching to subcutaneous MTX. The subcutaneous injection is the only parenteral form which can easily be administered at home.

keywords:

methotrexate, rheumatoid arthritis

EVENTS/KONFERENCJE

BOOKS/KSIĄŻKI

Review paperSubcutaneous methotrexate injection in the treatment of rheumatoid arthritis

Jerzy Świerkot

methotrexate, rheumatoid arthritis

Review paper
Subcutaneous methotrexate injection in the treatment of rheumatoid arthritis